Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer

Authors: Bo-lin Liu, Shu-juan Liu, Andrius Baskys, Hong Cheng, Ying Han, Chao Xie, Hui Song, Jia Li, Xiao-yan Xin

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

To characterize prognostic and risk factors of central nervous system (CNS) metastases in patients with epithelial ovarian cancer (EOC).

Methods

A retrospective analysis of Xijing Hospital electronic medical records was conducted to identify patients with pathologically confirmed EOC and CNS metastases. In addition to patient demographics, tumor pathology, treatment regimens, and clinical outcomes, we compared putative cancer stem cell marker CD133 expression patterns in primary and metastatic lesions as well as in recurrent EOC with and without CNS metastases.

Results

Among 1366 patients with EOC, metastatic CNS lesions were present in 29 (2.1%) cases. CD133 expression in primary tumor was the only independent risk factor for CNS metastases; whilst the extent of surgical resection of primary EOC and platinum resistance were two independent factors significantly associated with time to CNS metastases. Absence of CD133 expression in primary tumors was significantly associated with high platinum sensitivity in both patient groups with and without CNS metastases. Platinum resistance and CD133 cluster formation in CNS metastases were associated with decreased survival, while multimodal therapy including stereotactic radiosurgery (SRS) for CNS metastases was associated with increased survival following the diagnosis of CNS metastases.

Conclusions

These data suggest that there exist a positive association between CD133 expression in primary EOC, platinum resistance and the increased risk of CNS metastases, as well as a less favorable prognosis of EOC. The absence of CD133 clusters and use of multimodal therapy including SRS could improve the outcome of metastatic lesions. Further investigation is warranted to elucidate the true nature of the association between platinum sensitivity, CD133 expression, and the risk and prognosis of CNS metastases from EOC.
Appendix
Available only for authorised users
Literature
1.
Pectasides D, Pectasides M, Economopoulos T: Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist. 2006, 11: 252-260. 10.1634/theoncologist.11-3-252.CrossRefPubMed
2.
Bruzzone M, Campora E, Chiara S, Giudici S, Merlini L, Simoni C, Mammoliti S, Rubagotti A, Rosso R: Cerebral metastases secondary to ovarian cancer: still an unusual event. Gynecol Oncol. 1993, 49: 37-40. 10.1006/gyno.1993.1082.CrossRefPubMed
3.
Geisler JP, Geisler HE: Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol. 1995, 57: 246-249. 10.1006/gyno.1995.1134.CrossRefPubMed
4.
Pietzner K, Oskay-Oezcelik G, El Khalfaoui K, Boehmer D, Lichtenegger W, Sehouli J: Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res. 2009, 29: 2793-2798.PubMed
5.
Namikawa K, Asakura M, Minami T, Okazaki Y, Kadota E, Hashimoto S: Toxicity of cisplatin to the central nervous system of male rabbits. Biol Trace Elem Res. 2000, 74: 223-235. 10.1385/BTER:74:3:223.CrossRefPubMed
6.
Melichar B, Urminska H, Kohlova T, Nova M, Cesak T: Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol. 2004, 94: 267-276. 10.1016/j.ygyno.2004.05.026.CrossRefPubMed
7.
Sehouli J, Pietzner K, Harter P, Munstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G: Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol. 2010, 21: 2201-2205. 10.1093/annonc/mdq229.CrossRefPubMed
8.
Anupol N, Ghamande S, Odunsi K, Driscoll D, Lele S: Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol. 2002, 85: 487-492. 10.1006/gyno.2002.6653.CrossRefPubMed
9.
Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R: Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol. 2004, 66: 313-325.CrossRefPubMed
10.
Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L: Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003, 13: 125-129. 10.1046/j.1525-1438.2003.13054.x.CrossRefPubMed
11.
Kim TJ, Song S, Kim CK, Kim WY, Choi CH, Lee JH, Lee JW, Bae DS, Kim BG: Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2007, 17: 1252-1257. 10.1111/j.1525-1438.2007.00941.x.CrossRefPubMed
12.
Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA: Brain metastases from epithelial ovarian cancer. the Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005, 25: 3553-3558.PubMed
13.
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997, 90: 5013-5021.PubMed
14.
Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009, 28: 209-218. 10.1038/onc.2008.374.CrossRefPubMed
15.
Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009, 27: 2875-2883.PubMed
16.
Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68: 4311-4320. 10.1158/0008-5472.CAN-08-0364.CrossRefPubMedPubMedCentral
17.
Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J: CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2012, 25: 456-464. 10.1038/modpathol.2011.170.CrossRefPubMed
18.
Cheng JX, Liu BL, Zhang X: How powerful is CD133 as a cancer stem cell marker in brain tumors?. Cancer Treat Rev. 2009, 35: 403-408. 10.1016/j.ctrv.2009.03.002.CrossRefPubMed
19.
Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G: CD133 antigen expression in ovarian cancer. BMC Cancer. 2009, 9: 221-10.1186/1471-2407-9-221.CrossRefPubMedPubMedCentral
20.
Liao Y, Hu X, Huang X, He C: Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biol Pharm Bull. 2010, 33: 738-742. 10.1248/bpb.33.738.CrossRefPubMed
21.
Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008, 14: 123-129. 10.1158/1078-0432.CCR-07-0932.CrossRefPubMed
22.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002, 20: 1248-1259. 10.1200/JCO.20.5.1248.CrossRefPubMed
23.
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R: Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011, 10: CD007565
24.
Mizrak D, Brittan M, Alison M: CD133: molecule of the moment. J Pathol. 2008, 214: 3-9. 10.1002/path.2283.CrossRefPubMed
25.
Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, Xu XD, Yu ED, Rui YC, Liu HJ, Zhang L, Wei LX: CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 2012, 10: 85-10.1186/1741-7015-10-85.CrossRefPubMedPubMedCentral
26.
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007, 1: 313-323. 10.1016/j.stem.2007.06.002.CrossRefPubMed
27.
Chen K, Li Z, Jiang P, Zhang X, Zhang Y, Jiang Y, He Y, Li X: Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncol Rep. 2014, 32: 755-763.PubMed
28.
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008, 118: 2111-2120.PubMedPubMedCentral
29.
Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M: CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mullerian tumor). Stem Cells. 2011, 29: 1485-1495. 10.1002/stem.711.CrossRefPubMed
30.
Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD: Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol. 2007, 196: 245-e241-211CrossRefPubMed
31.
Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D, Coenegrachts L, Cano A, Gil-Moreno A, Chiva L, Cueva J, Vieito M, Ortega E, Mariscal J, Colas E, Castellvi J, Cusido M, Dolcet X, Nijman HW, Bosse T, Green JA, Romano A, Reventos J, Lopez-Lopez R, Salvesen HB, Amant F, Matias-Guiu X, Moreno-Bueno G, et al: Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer. 2014, 13: 223-10.1186/1476-4598-13-223.CrossRefPubMedPubMedCentral
32.
Pakneshan S, Safarpour D, Tavassoli F, Jabbari B: Brain metastasis from ovarian cancer: a systematic review. J Neurooncol. 2014, 119: 1-6. 10.1007/s11060-014-1447-9.CrossRefPubMed
33.
Adler JR, Cox RS, Kaplan I, Martin DP: Stereotactic radiosurgical treatment of brain metastases. J Neurosurg. 1992, 76: 444-449. 10.3171/jns.1992.76.3.0444.CrossRefPubMed
34.
Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst. 1995, 87: 34-40. 10.1093/jnci/87.1.34.CrossRefPubMed
35.
Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP: Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol Oncol. 2008, 108: 505-509. 10.1016/j.ygyno.2007.11.027.CrossRefPubMed
36.
Brodsky AS, Fischer A, Miller DH, Vang S, MacLaughlan S, Wu HT, Yu J, Steinhoff M, Collins C, Smith PJ, Raphael BJ, Brard L: Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One. 2014, 9: e94476-10.1371/journal.pone.0094476.CrossRefPubMedPubMedCentral
37.
Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, Iversen ES, Berchuck A, Murphy SK: Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res. 2011, 21: 74-82. 10.1101/gr.108803.110.CrossRefPubMedPubMedCentral
38.
Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, Konishi I: The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012, 130: 20-28. 10.1002/ijc.25961.CrossRefPubMed
39.
Baba T, Mori S, Matsumura N, Kariya M, Murphy SK, Kondoh E, Kusakari T, Kuroda H, Mandai M, Higuchi T, Takakura K, Fukuda MN, Fujii S: Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. Biochem Biophys Res Commun. 2007, 360: 363-369. 10.1016/j.bbrc.2007.06.070.CrossRefPubMed
40.
Hamanishi J, Mandai M, Abiko K, Matsumura N, Baba T, Yoshioka Y, Kosaka K, Konishi I: The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol. 2011, 141: 338-347. 10.1016/j.clim.2011.08.013.CrossRefPubMed
41.
Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I: PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res. 2013, 19: 1363-1374. 10.1158/1078-0432.CCR-12-2199.CrossRefPubMed
42.
Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A: Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol. 2010, 116: 556-562. 10.1016/j.ygyno.2009.11.020.CrossRefPubMed
Metadata
Title
Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer
Authors
Bo-lin Liu
Shu-juan Liu
Andrius Baskys
Hong Cheng
Ying Han
Chao Xie
Hui Song
Jia Li
Xiao-yan Xin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-829

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka

Research article

A retrospective analysis of survival and prognostic factors of male breast cancer from a single center

Research article

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

Research article

Regional variation in breast cancer treatment in the Netherlands and the role of external peer review: a cohort study comprising 63,516 women

Research article

MicroRNA profile in very young women with breast cancer

Research article

Clinical relevance of breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits